Aldeyra Therapeutics, Inc. (ALDX)
1.48
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
1.48
0.00 (0.00%)
After-Hours: 20:00
Aldeyra Therapeutics Cash from Investing (Quarterly) : -0.0231M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0231M |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 16.00M |
| September 30, 2025 | 25.00M |
| June 30, 2025 | -0.5541M |
| March 31, 2025 | 7.290M |
| December 31, 2024 | -1.564M |
| September 30, 2024 | 5.263M |
| June 30, 2024 | -18.24M |
| March 31, 2024 | -30.38M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 30.00M |
| December 31, 2022 | 27.00M |
| September 30, 2022 | 19.02M |
| June 30, 2022 | -17.94M |
| March 31, 2022 | -58.03M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -0.0078M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 5.50M |
| June 30, 2020 | 17.30M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.224M |
| December 31, 2019 | -4.285M |
| September 30, 2019 | 5.676M |
| June 30, 2019 | 7.922M |
| March 31, 2019 | 9.164M |
| December 31, 2018 | -28.97M |
| September 30, 2018 | -0.0213M |
| June 30, 2018 | 0.8566M |
| March 31, 2018 | 4.802M |
| December 31, 2017 | -8.11M |
| September 30, 2017 | -3.628M |
| June 30, 2017 | 0.6485M |
| March 31, 2017 | 0.8915M |
| December 31, 2016 | 1.320M |
| September 30, 2016 | 0.5667M |
| June 30, 2016 | -2.103M |
| March 31, 2016 | -0.0092M |
| December 31, 2015 | -12.95M |
| September 30, 2015 | -0.0542M |
| June 30, 2015 | -0.0304M |
| March 31, 2015 | -0.0014M |
| December 31, 2014 | -0.008M |
| September 30, 2014 | -0.0061M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
| Sarepta Therapeutics, Inc. | -93.37M |
| Anixa Biosciences, Inc. | 0.422M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.589M |
| Cash from Financing (Quarterly) | -15.30M |
| Free Cash Flow | -22.04M |
| Free Cash Flow Per Share (Quarterly) | -0.0765 |
| Free Cash Flow to Equity (Quarterly) | 10.76M |
| Free Cash Flow to Firm (Quarterly) | -4.612M |
| Free Cash Flow Yield | -24.73% |